(+/-)-tert-butyl 1-(1H-imidazol-2-yl)-2-(7-methyl-2-[{2-[trimethylsilyl]ethoxy}methyl]-2H-indazol-5-yl)ethylcarbamate | 855777-79-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: (+/-)-tert-butyl 1-(1H-imidazol-2-yl)-2-(7-methyl-2-[{2-[trimethylsilyl]ethoxy}methyl]-2H-indazol-5-yl)ethylcarbamate
• 英文别名: tert-Butyl-1-(1H-imidazol-2-yl)-2-(7-methyl-2-[{2-[trimethylsilyl]ethoxy}methyl]-2H-indazol-5-yl)ethylcarbamate；tert-butyl N-[1-(1H-imidazol-2-yl)-2-[7-methyl-2-(2-trimethylsilylethoxymethyl)indazol-5-yl]ethyl]carbamate
• CAS: 855777-79-6
• 化学式: C₂₄H₃₇N₅O₃Si
• 分子量: 471.675
• InChiKey: DGLGUWIPOGCJSC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.19
• 重原子数：
  33
• 可旋转键数：
  11
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  94.1
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (+/-)-tert-butyl 1-(1H-imidazol-2-yl)-2-(7-methyl-2-[{2-[trimethylsilyl]ethoxy}methyl]-2H-indazol-5-yl)ethylcarbamate 在 三氟乙酸 、 氨 作用下， 以 二氯甲烷 、 甲醇 为溶剂， 反应 3.0h， 生成 1-(1H-imidazol-2-yl)-2-(7-methyl-1H-indazol-5-yl)ethan-1-amine
  参考文献：
  名称：

  [EN] HETEROCYCLIC ANTI-MIGRAINE AGENTS
  [FR] ANTIMIGRAINEUX HETEROCYCLIQUES

  摘要：

  公开号：

  WO2005056550A3
• 作为产物：
  描述：

  trimethyl 2-(tert-butoxycarbonylamino)phosphonoacetate 在 ammonium hydroxide 、 锂硼氢 、 palladium on activated charcoal 、 氢气 、 三氧化硫吡啶 、 三乙胺 、 四甲基胍 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 水 、 二甲基亚砜 为溶剂， 生成 (+/-)-tert-butyl 1-(1H-imidazol-2-yl)-2-(7-methyl-2-[{2-[trimethylsilyl]ethoxy}methyl]-2H-indazol-5-yl)ethylcarbamate
  参考文献：
  名称：

  Preparation of imidazoles as potent calcitonin gene-related peptide (CGRP) antagonists

  摘要：

  Several new potent CGRP receptor antagonists have been prepared in which the amide bond of lead compound 1 has been replaced by bioisosteric imidazole moieties. Substitution at N-1 of the imidazole was optimized to afford compounds with comparable potency to that of lead 1. Conformational restraint of the imidazole to form tetrahydroimidazo[1,5-a] pyrazine 43 gave substantially improved permeability. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.08.031

文献信息

• Heterocyclic anti-migraine agents
  申请人：Luo Guanglin

  公开号：US20050153959A1

  公开（公告）日：2005-07-14

  The present invention relates to compounds of Formula (I) as antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

  本发明涉及公式(I)的化合物作为降钙素基因相关肽受体（“CGRP受体”）拮抗剂，包括它们的制药组合物、鉴定它们的方法、使用它们的治疗方法以及它们在治疗神经源性血管扩张、神经源性炎症、偏头痛和其他头痛、热损伤、循环性休克、与绝经期相关的潮红、气道炎症性疾病（如哮喘和慢性阻塞性肺疾病（COPD））以及其他可以通过CGRP受体拮抗来治疗的病症的治疗中的应用。
• [EN] HETEROCYCLIC ANTI-MIGRAINE AGENTS<br/>[FR] ANTIMIGRAINEUX HETEROCYCLIQUES
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2005056550A3

  公开（公告）日：2005-07-14
• Preparation of imidazoles as potent calcitonin gene-related peptide (CGRP) antagonists
  作者：George Tora、Andrew P. Degnan、Charles M. Conway、Walter A. Kostich、Carl D. Davis、Sokhom S. Pin、Richard Schartman、Cen Xu、Kimberly A. Widmann、John E. Macor、Gene M. Dubowchik

  DOI：10.1016/j.bmcl.2013.08.031

  日期：2013.10

  Several new potent CGRP receptor antagonists have been prepared in which the amide bond of lead compound 1 has been replaced by bioisosteric imidazole moieties. Substitution at N-1 of the imidazole was optimized to afford compounds with comparable potency to that of lead 1. Conformational restraint of the imidazole to form tetrahydroimidazo[1,5-a] pyrazine 43 gave substantially improved permeability. (C) 2013 Elsevier Ltd. All rights reserved.